A Phase 2 clinical trial conducted by Johnson & Johnson to assess the effectiveness of their antiviral candidate, mosnodenvir (formerly JNJ-1802), for the prevention of dengue virus in adults between the ages of 18 and 65, has been discontinued. The corporation has switched priority to other areas in its health activities as part of its strategic reprioritization of its research and development portfolio related to communicable diseases, which includes this decision. Crucially, there were no safety concerns found with the antiviral, and the decision was made only because of a shift in strategic goals.
Mosnodenvir had demonstrated potential in past experiments. Clinical trials in phases 1 and 2a showed that the medication was both safe and well-tolerated by subjects. Specifically, mosnodenvir demonstrated antiviral effectiveness against dengue virus type 3 (DENV-3) in comparison to a placebo, according to a Phase 2a human challenge research. These results have sparked optimism about its potential as a treatment to prevent dengue, which is still a major public health concern in tropical and subtropical areas.
The trial, formally designated NCT05201794, has been terminated once participants have fulfilled their participation requirements in accordance with the protocol. The trial’s final efficacy statistics are presently being analyzed by Johnson & Johnson; once available, the findings will be disseminated to the medical community and study investigators. Even though the field trial will no longer be conducted, the company is dedicated to sharing its research findings and helping the global fight against dengue.
Johnson & Johnson is still committed to tackling the problem of communicable diseases, which cause millions of illnesses and fatalities worldwide every year. The company’s program for communicable illnesses covers a number of important health issues, including as leprosy and other neglected tropical diseases, HIV, extraintestinal pathogenic E. coli (ExPEC), and tuberculosis. This program expands on decades of study that aims to make the world safer and healthier while also enhancing lives.
Johnson & Johnson’s wider commitment to allocating its resources to areas where they can have the biggest effects is reflected in the decision to terminate the project. Even though Mosnodenvir’s adventure to prevent dengue fever is over, the company continues to fight communicable diseases through its other projects and ongoing research. People can visit Johnson & Johnson’s Innovative Medicine website to learn more about the company’s initiatives.
SOURCE :
JOHNSON & JOHNSON
